PPARα agonist exerts protective effects in podocyte injury via inhibition of the ANGPTL3 pathway
- 1 October 2021
- journal article
- research article
- Published by Elsevier in Experimental Cell Research
- Vol. 407 (2) , 112753
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81700626)
- National Natural Science Foundation of China (81670609)
- National Natural Science Foundation of China (8187359)
- National Natural Science Foundation of China (81700626,81670609,8187359)
This publication has 24 references indexed in Scilit:
- Beneficial effects of fenofibrate in retinal pigment epithelium by the modulation of stress and survival signaling under diabetic conditionsJournal of Cellular Physiology, 2011
- Peroxisome proliferator-activated receptor-α is renoprotective in doxorubicin-induced glomerular injuryKidney International, 2011
- PPAR-α transcriptional activity is required to combat doxorubicin-induced podocyte injury in miceKidney International, 2011
- The subtypes of peroxisome proliferator‐activated receptors expressed by human podocytes and their role in decreasing podocyte injuryBritish Journal of Pharmacology, 2010
- Expression of Angiopoietin-Like 3 Associated with Puromycin-Induced Podocyte DamageNephron Experimental Nephrology, 2010
- Gemfibrozil, stretching arms beyond lipid loweringImmunopharmacology and Immunotoxicology, 2009
- Effects of Intensive Glucose Lowering in Type 2 DiabetesNew England Journal of Medicine, 2008
- Podocytes in culture: past, present, and futureKidney International, 2007
- The podocyte's response to injury: Role in proteinuria and glomerulosclerosisKidney International, 2006
- PPARα agonist fenofibrate improves diabetic nephropathy in db/db miceKidney International, 2006